Drug Profile
Research programme: immunomodulators - AsclepiX Therapeutics
Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator AsclepiX Therapeutics
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Unspecified in USA
- 28 Dec 2021 Early research is ongoing in USA (AsclepiX Therapeutics pipeline, December 2021)